Lonza, a worldwide manufacturing partner to the pharma, biotech, and nutrition industries, is investing in expanding drug product manufacturing capabilities in Switzerland with an additional aseptic flexible filling line for clinical drug product supply in Stein (CH).
The new line will support liquid and lyophilized vial filling, cartridges, and pre-filled syringes. It will handle various modalities, including monoclonal antibodies, bio-conjugates, viral vectors, and gene therapy products.
The line will use advanced robotic technology and implement innovative freeze-drying technology with a sustainable air-cooling system.
The installation is expected to be completed in 2023 and will create over 70 new jobs at the Stein site. The investment also includes expanding Drug Product Services (DPS) for parenteral dosage forms in Basel (CH), supporting drug development for early and late clinical stages and increasing process development and characterization capabilities.
The new DPS facilities in Basel are expected to be operational in 2024. Jean-Christophe Hyvert, President, Biologics and Cell and Gene at Lonza, commented, "The expansion of our drug product capabilities in Switzerland provides our clients with access to an integrated offering, including development, testing, and manufacturing services for mammalian, microbial, bio-conjugate products, cell and gene therapies, and small molecules."
He further emphasized that this investment reinforces Lonza’s commitment to providing a full solution across various modalities and scales.
No comments:
Post a Comment